The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dry Eye Syndrome Drugs Market Research Report 2024
Synopsis
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
The global Dry Eye Syndrome Drugs market was valued at US$ 5385 million in 2023 and is anticipated to reach US$ 6838.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Dry Eye Syndrome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Eye Syndrome Drugs.
Report Scope
The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Eye Syndrome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Novartis
Santen
Takeda
Otsuka
Eyegate Pharma
Can-Fite BioPharma
Bausch and Lomb
Auven Therapeutics (Celtic)
Bridge Pharma
Cellzome
Segment by Type
Antibiotic Drops
Hormone Drops
Artificial Tears
Segment by Application
Hospitals
Clinics
Household Use
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dry Eye Syndrome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
The global Dry Eye Syndrome Drugs market was valued at US$ 5385 million in 2023 and is anticipated to reach US$ 6838.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Dry Eye Syndrome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Eye Syndrome Drugs.
Report Scope
The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Eye Syndrome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Novartis
Santen
Takeda
Otsuka
Eyegate Pharma
Can-Fite BioPharma
Bausch and Lomb
Auven Therapeutics (Celtic)
Bridge Pharma
Cellzome
Segment by Type
Antibiotic Drops
Hormone Drops
Artificial Tears
Segment by Application
Hospitals
Clinics
Household Use
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dry Eye Syndrome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dry Eye Syndrome Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibiotic Drops
1.2.3 Hormone Drops
1.2.4 Artificial Tears
1.3 Market by Application
1.3.1 Global Dry Eye Syndrome Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Household Use
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dry Eye Syndrome Drugs Market Perspective (2019-2030)
2.2 Dry Eye Syndrome Drugs Growth Trends by Region
2.2.1 Global Dry Eye Syndrome Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Dry Eye Syndrome Drugs Historic Market Size by Region (2019-2024)
2.2.3 Dry Eye Syndrome Drugs Forecasted Market Size by Region (2025-2030)
2.3 Dry Eye Syndrome Drugs Market Dynamics
2.3.1 Dry Eye Syndrome Drugs Industry Trends
2.3.2 Dry Eye Syndrome Drugs Market Drivers
2.3.3 Dry Eye Syndrome Drugs Market Challenges
2.3.4 Dry Eye Syndrome Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dry Eye Syndrome Drugs Players by Revenue
3.1.1 Global Top Dry Eye Syndrome Drugs Players by Revenue (2019-2024)
3.1.2 Global Dry Eye Syndrome Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Dry Eye Syndrome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dry Eye Syndrome Drugs Revenue
3.4 Global Dry Eye Syndrome Drugs Market Concentration Ratio
3.4.1 Global Dry Eye Syndrome Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dry Eye Syndrome Drugs Revenue in 2023
3.5 Dry Eye Syndrome Drugs Key Players Head office and Area Served
3.6 Key Players Dry Eye Syndrome Drugs Product Solution and Service
3.7 Date of Enter into Dry Eye Syndrome Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dry Eye Syndrome Drugs Breakdown Data by Type
4.1 Global Dry Eye Syndrome Drugs Historic Market Size by Type (2019-2024)
4.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Type (2025-2030)
5 Dry Eye Syndrome Drugs Breakdown Data by Application
5.1 Global Dry Eye Syndrome Drugs Historic Market Size by Application (2019-2024)
5.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Dry Eye Syndrome Drugs Market Size (2019-2030)
6.2 North America Dry Eye Syndrome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Dry Eye Syndrome Drugs Market Size by Country (2019-2024)
6.4 North America Dry Eye Syndrome Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dry Eye Syndrome Drugs Market Size (2019-2030)
7.2 Europe Dry Eye Syndrome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Dry Eye Syndrome Drugs Market Size by Country (2019-2024)
7.4 Europe Dry Eye Syndrome Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dry Eye Syndrome Drugs Market Size (2019-2030)
8.2 Asia-Pacific Dry Eye Syndrome Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Dry Eye Syndrome Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Dry Eye Syndrome Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dry Eye Syndrome Drugs Market Size (2019-2030)
9.2 Latin America Dry Eye Syndrome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Dry Eye Syndrome Drugs Market Size by Country (2019-2024)
9.4 Latin America Dry Eye Syndrome Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dry Eye Syndrome Drugs Market Size (2019-2030)
10.2 Middle East & Africa Dry Eye Syndrome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Dry Eye Syndrome Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Dry Eye Syndrome Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Dry Eye Syndrome Drugs Introduction
11.1.4 Allergan Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.1.5 Allergan Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Dry Eye Syndrome Drugs Introduction
11.2.4 Novartis Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Santen
11.3.1 Santen Company Detail
11.3.2 Santen Business Overview
11.3.3 Santen Dry Eye Syndrome Drugs Introduction
11.3.4 Santen Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.3.5 Santen Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Dry Eye Syndrome Drugs Introduction
11.4.4 Takeda Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Otsuka
11.5.1 Otsuka Company Detail
11.5.2 Otsuka Business Overview
11.5.3 Otsuka Dry Eye Syndrome Drugs Introduction
11.5.4 Otsuka Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.5.5 Otsuka Recent Development
11.6 Eyegate Pharma
11.6.1 Eyegate Pharma Company Detail
11.6.2 Eyegate Pharma Business Overview
11.6.3 Eyegate Pharma Dry Eye Syndrome Drugs Introduction
11.6.4 Eyegate Pharma Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.6.5 Eyegate Pharma Recent Development
11.7 Can-Fite BioPharma
11.7.1 Can-Fite BioPharma Company Detail
11.7.2 Can-Fite BioPharma Business Overview
11.7.3 Can-Fite BioPharma Dry Eye Syndrome Drugs Introduction
11.7.4 Can-Fite BioPharma Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.7.5 Can-Fite BioPharma Recent Development
11.8 Bausch and Lomb
11.8.1 Bausch and Lomb Company Detail
11.8.2 Bausch and Lomb Business Overview
11.8.3 Bausch and Lomb Dry Eye Syndrome Drugs Introduction
11.8.4 Bausch and Lomb Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.8.5 Bausch and Lomb Recent Development
11.9 Auven Therapeutics (Celtic)
11.9.1 Auven Therapeutics (Celtic) Company Detail
11.9.2 Auven Therapeutics (Celtic) Business Overview
11.9.3 Auven Therapeutics (Celtic) Dry Eye Syndrome Drugs Introduction
11.9.4 Auven Therapeutics (Celtic) Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.9.5 Auven Therapeutics (Celtic) Recent Development
11.10 Bridge Pharma
11.10.1 Bridge Pharma Company Detail
11.10.2 Bridge Pharma Business Overview
11.10.3 Bridge Pharma Dry Eye Syndrome Drugs Introduction
11.10.4 Bridge Pharma Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.10.5 Bridge Pharma Recent Development
11.11 Cellzome
11.11.1 Cellzome Company Detail
11.11.2 Cellzome Business Overview
11.11.3 Cellzome Dry Eye Syndrome Drugs Introduction
11.11.4 Cellzome Revenue in Dry Eye Syndrome Drugs Business (2019-2024)
11.11.5 Cellzome Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
